Boehringer Ingelheim – German Quality Traditions in Medicine
Boehringer Ingelheim
Boehringer Ingelheim is a German pharmaceutical company founded in 1885 by Albert Boehringer and headquartered in Ingelheim am Rhein. It is not publicly listed: the company is wholly owned by the Boehringer, Liebrecht and von Baumbach families, descendants of the founder.
The company has two businesses: human pharmaceuticals and animal health. In human medicine its main areas are respiratory diseases, cardiovascular and metabolic diseases, and oncology.
Its well-known original medicines include Spiriva (tiotropium) for COPD, the anticoagulant Pradaxa (dabigatran), Trajenta (linagliptin) and Jardiance (empagliflozin) for type 2 diabetes, and Ofev (nintedanib) for idiopathic pulmonary fibrosis and other fibrosing lung diseases. Since 2011 Boehringer Ingelheim has developed its diabetes medicines in an alliance with Eli Lilly.
In 2025 the company reported revenue of 27.8 billion euros and employed about 54,000 people.
Unifarm carries Boehringer Ingelheim medicines: Ofev 100 and Ofev 150 (nintedanib) and Glyxambi (empagliflozin + linagliptin).